Company
Boehringer Ingelheim
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
54
28 still marketed
Novel approvals
21
Approvals since 2021
29
Originals and new uses
Phase 3 trials
392
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Hernexeos new use Breakthrough therapyPriority reviewFeb 26, 2026
- Jascayd approved Breakthrough therapyPriority reviewOrphanDec 19, 2025
- Jascayd approved NovelBreakthrough therapyPriority reviewOrphanOct 7, 2025
- Hernexeos approved NovelBreakthrough therapyAccelerated approvalPriority reviewAug 8, 2025
- Spevigo new use OrphanMay 28, 2025
- Cyltezo new use May 20, 2025
- Synjardy new use Mar 7, 2025
- Synjardy Xr new use Mar 7, 2025
- Cyltezo new use Apr 30, 2024
- Spevigo new use Breakthrough therapyOrphanMar 18, 2024
Drugs in development (25)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- ObrixtamigBI 764532Phase 36 trials
Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- VerducatibBI 1291583Phase 34 trials
Boehringer Ingelheim · Bronchiectasis, Chronic Obstructive Pulmonary Disease
- BI 764198ApecotrepPhase 33 trials
Boehringer Ingelheim · Focal Segmental Glomerulosclerosis, Proteinuric Kidney Diseases, Kidney Disease, Chronic
- BrigimadlinBI 907828Phase 33 trials
Boehringer Ingelheim · Solid Tumours, Pancreatic Neoplasms, Solid Tumors
- SurvodutideBI 456906Phase 33 trials
Boehringer Ingelheim · Obesity, Type 2 Diabetes, Overweight
- ZL-1310Phase 33 trials
Zai Lab (Shanghai) Co., Ltd. · Solid Tumors, Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma
- BI 1015550Phase 32 trials
Boehringer Ingelheim · Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis
- EzabenlimabBI 754091Phase 32 trials
Boehringer Ingelheim · Advanced Cancer, Neoplasm Metastasis, Advanced Tumors
- BI 1569912Phase 22 trials
Boehringer Ingelheim · Depressive Disorder, Major
- BI 1584862Phase 21 trial
Boehringer Ingelheim · Geographic Atrophy
- BI 1815368Phase 21 trial
Boehringer Ingelheim · Macular Edema
- BI 1819479Phase 21 trial
Boehringer Ingelheim · Idiopathic Pulmonary Fibrosis
- BI 3000202Phase 21 trial
Boehringer Ingelheim · Systemic Lupus Erythematosus
- BI 3032950Phase 21 trial
Boehringer Ingelheim · Ulcerative Colitis
- BI 3034701Phase 21 trial
Boehringer Ingelheim · Obesity, Overweight
- BI 3802876Phase 21 trial
Boehringer Ingelheim · Liver Cirrhosis
- BI 3810477Phase 21 trial
Boehringer Ingelheim · Idiopathic Pulmonary Fibrosis
- BI 3812465Phase 21 trial
Boehringer Ingelheim · Diabetic Macular Edema
- BI 754111Phase 21 trial
Boehringer Ingelheim · Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors
- BI 764524Phase 21 trial
Boehringer Ingelheim · Diabetic Retinopathy
- BI 765423Phase 21 trial
Boehringer Ingelheim · Idiopathic Pulmonary Fibrosis
- BI 770371Phase 21 trial
Boehringer Ingelheim · Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)
- BI 771716Phase 21 trial
Boehringer Ingelheim · Macular Degeneration, Age-related, Geographic Atrophy
- BI 836880Phase 21 trial
Boehringer Ingelheim · Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors
Recruiting Phase 3 trials
Largest first.
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseasePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07064473 · 11,800 participants (planned) · Start Jul 22, 2025 · Primary completion Dec 14, 2029
Drug: Vicadrostat; Empagliflozin and 1 more · For: Diabetes Mellitus, Type 2; Hypertension; Cardiovascular Diseases
Sites: Anniston, Alabama; Fairhope, Alabama; Guntersville, Alabama · 1,142 sites in all
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailurePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06424288 · 6,712 participants (planned) · Start Jun 17, 2024 · Primary completion May 22, 2028
Drug: vicadrostat; empagliflozin and 1 more · For: Heart Failure
Sites: Mobile, Alabama; Chula Vista, California; Orange, California · 672 sites in all
- A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06935370 · 4,200 participants (planned) · Start May 20, 2025 · Primary completion Feb 4, 2029
Drug: vicadrostat; empagliflozin and 1 more · For: Heart Failure
Sites: Beverly Hills, California; Covina, California; Encinitas, California · 596 sites in all
- The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With BronchiectasisPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06872892 · 1,755 participants (planned) · Start Jun 9, 2025 · Primary completion Jun 15, 2027
Drug: BI 1291583; Placebo matching BI 1291583 · For: Bronchiectasis
Sites: Birmingham, Alabama; Tucson, Arizona; Newport Beach, California · 474 sites in all
- A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen WellPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07361302 · 1,325 participants (planned) · Start Feb 17, 2026 · Primary completion Oct 2, 2027
Drug: Tenecteplase; Standard of care treatment · For: Acute Ischemic Stroke
Sites: Buenos Aires, Argentina; Ciudad Autonoma Buenos Aires, Argentina; Córdoba, Argentina · 258 sites in all
- DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07472517 · 670 participants (planned) · Start Apr 13, 2026 · Primary completion Sep 9, 2028
Drug: obrixtamig; atezolizumab and 2 more · For: Small Cell Lung Cancer (SCLC); Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Sites: Mobile, Alabama; Little Rock, Arkansas; Hialeah, Florida · 242 sites in all
- A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07754461 · 600 participants (planned) · Start Aug 24, 2026 · Primary completion Jan 17, 2028
Drug: Placebo; Survodutide · For: Type 2 Diabetes
Sites: Birmingham, Alabama; Gilbert, Arizona; Paradise Valley, Arizona · 121 sites in all
- FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease ProgressionPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07540988 · 466 participants (planned) · Start Sep 17, 2026 · Primary completion Dec 5, 2028
Drug: Nerandomilast; Placebo matching nerandomilast · For: Interstitial Lung Diseases
Sites: Birmingham, Alabama; Los Angeles, California; Newport Beach, California · 162 sites in all
- A Study to Test Whether Nerandomilast Helps People With Systemic SclerosisPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07497087 · 448 participants (planned) · Start Jul 27, 2026 · Primary completion Feb 26, 2030
Drug: Placebo matching nerandomilast formulation 1; Placebo matching nerandomilast formulation 2 and 2 more · For: Systemic Sclerosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 248 sites in all
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07195695 · 400 participants (planned) · Start Jan 16, 2026 · Primary completion Feb 26, 2032
Drug: Zongertinib; Pembrolizumab and 3 more · For: Non-small Cell Lung Cancer
Sites: Fresno, California; Glendale, California; Orange, California · 205 sites in all
Marketed drugs (28)
Newest FDA action first.
- Jascayd Nerandomilast · 2025
- Synjardy Empagliflozin, Metformin Hydrochloride · 2015
- Jentadueto Linagliptin, Metformin Hydrochloride · 2012
- Jentadueto Xr Linagliptin, Metformin Hydrochloride · 2016
- Synjardy Xr Empagliflozin, Metformin Hydrochloride · 2016
- Trijardy Xr Empagliflozin, Linagliptin, Metformin Hydrochloride · 2020
- Hernexeos Zongertinib · 2025
- Jascayd Nerandomilast · 2025
- Jardiance Empagliflozin · 2014
- Glyxambi Empagliflozin, Linagliptin · 2015
- Spevigo Spesolimab-Sbzo · 2022
- Cyltezo Adalimumab-Adbm · 2017
- Pradaxa Dabigatran Etexilate Mesylate · 2010
- Atrovent Hfa Ipratropium Bromide · 2004
- Spiriva Tiotropium Bromide · 2004
- Stiolto Respimat Olodaterol Hydrochloride, Tiotropium Bromide · 2015
- Striverdi Respimat Olodaterol Hydrochloride · 2014
- Spiriva Respimat Tiotropium Bromide · 2014
- Ofev Nintedanib Esylate · 2014
- Aptivus Tipranavir · 2005
- Tradjenta Linagliptin · 2011
- Micardis Hct Hydrochlorothiazide, Telmisartan · 2000
- Gilotrif Afatinib Dimaleate · 2013
- Praxbind Idarucizumab · 2015
- Combivent Respimat Albuterol Sulfate, Ipratropium Bromide · 2011
- Spiriva Respimat Tiotropium Bromide · 2015
- Mirapex Er Pramipexole Dihydrochloride · 2010
- Aptivus Tipranavir · 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.